Compare MRCY & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCY | PTCT |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 1997 | 2006 |
| Metric | MRCY | PTCT |
|---|---|---|
| Price | $78.01 | $63.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $114.80 | $101.07 |
| AVG Volume (30 Days) | 568.9K | ★ 1.2M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.08 | ★ 264.48 |
| EPS | N/A | ★ 0.90 |
| Revenue | ★ $983,622,000.00 | $264,734,000.00 |
| Revenue This Year | $10.46 | N/A |
| Revenue Next Year | $11.44 | $9.26 |
| P/E Ratio | ★ N/A | $71.38 |
| Revenue Growth | 7.85 | ★ 36.19 |
| 52 Week Low | $65.04 | $61.23 |
| 52 Week High | $128.45 | $90.87 |
| Indicator | MRCY | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 40.49 |
| Support Level | $73.38 | $62.46 |
| Resistance Level | $89.06 | $72.86 |
| Average True Range (ATR) | 2.31 | 2.00 |
| MACD | 0.00 | 0.19 |
| Stochastic Oscillator | 7.71 | 38.57 |
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.